Investing.com's Fair Value model demonstrated its effectiveness once again, identifying a significant opportunity in BioNTech SE (NASDAQ:BNTX) that resulted in a remarkable 51% return over just six ...

The rest is history – Pfizer stepped in and licensed the technology, choosing the most promising of four potential mRNA vaccines from BioNTech. Both Moderna and Pfizer’s shots aced the quickly ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus ...

Cellscript), so other firms could also license the fundamental technology allowing mRNA to function as a therapeutic. In fact, while Moderna, CureVac, BioNTech, and GSK historically dominated mRNA ...

The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

BioNTech SE is advancing its oncology ... with investigational combination therapies in two pan-tumor technology pillars: our mRNA-based cancer immunotherapies for the early, adjuvant setting ...

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

The same mRNA technology behind COVID-19 vaccines is now being used in the fight against cancer, and the University of ...

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.